Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 plus etoposide and platinum as first-line therapy for advanced neuroendocrine carcinoma
CTR20233858Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in neuroendocrine carcinoma (NEC), small cell lung cancer (SCLC), sponsored by Leads Biolabs. Started Jan 2024; status: active.
02
Drugs
opamtistomig
03
Conditions
neuroendocrine carcinoma (NEC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20233858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233858.